Online inquiry

IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9198MR)

This product GTTS-WQ9198MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets FOLR1 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_000802.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2348
UniProt ID P15328
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ9198MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12057MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ1236MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-165
GTTS-WQ14750MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-35
GTTS-WQ10374MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY2062430
GTTS-WQ5493MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CDP 6038
GTTS-WQ554MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 4D5-8
GTTS-WQ14946MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SHR-1210
GTTS-WQ5891MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CIM 331
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW